News

The latest from Velocity Clinical Research

Paul Evans Named Among the Top 50 Healthcare Technology CEOs of 2024

January 8, 2025

Congratulations to Paul Evans for being named one of the Top 50 Healthcare Technology CEOs of 2024! With Paul’s leadership, Velocity continues to redefine how clinical trials are conducted — leveraging VISION technology, centralization, and global site integration to accelerate drug development. His recognition … Read more

Velocity Contributes to ACRP Whitepaper on Responsible AI Oversight

January 7, 2025

Velocity’s team contributed to the new Association of Clinical Research Professionals (ACRP) comprehensive whitepaper, titled ‘Responsible Oversight of Artificial Intelligence for Clinical Research Professionals.’ The development of our VISION technology has coincided with the proliferation of AI and large language models (LLMs). For recruitment … Read more

BioSpace Opinion: The Cocktail Recipe That Will Cure Alzheimer’s

January 6, 2025

Robert Cupelo, MD, Principal Investigator in Syracuse, NY, shares his firsthand insights into the evolving landscape of Alzheimer’s treatment. Nearly two years after the FDA’s approval of lecanemab (Leqembi), and with the subsequent approval of donanemab (Kisunla), researchers are making crucial steps forward in … Read more

Fierce Biotech Article: Paul Evans on Clinical Trials in 2025

December 30, 2024

A new Fierce Biotech article features insights from Paul Evans on what to expect for clinical research in 2025. Topics include rising costs and uncertain regulations, as well as the continued emergence of site networks, AI-driven efficiency (with technology built “by trial sites, for … Read more

2025 Clinical Trials Outlook: Six Industry Trends to Expect

December 23, 2024

Rising costs, evolving regulations, and the unstoppable growth of AI are set to shape clinical trials in 2025. How will sites, new tech, promising obesity drugs, and shifting policies affect our industry? Read this article from Paul Evans featured on PharmiWeb: https://www.pharmiweb.com/article/2025-clinical-trials-outlook-six-industry-trends-to-expect

Henrik Watz Featured in Free Educational Presentation Available for HCPs on COPD with Type 2 Inflammation

December 4, 2024

Congratulations to Henrik Watz, MD, on his exceptional presentation at the 2024 European Respiratory Society (ERS) ADVENT COPD Symposia! Dr. Watz, Medical Director and Principal Investigator at Velocity Clinical Research in Ahrensburg, Germany, joined Drs. Mona Bafadhel and Alberto Papi for a dynamic discussion, … Read more

Velocity Targets Latin America Expansion with the Appointment of Renata Berardocco as LATAM Managing Director

November 21, 2024

Velocity Clinical Research, the leading fully integrated clinical site organization, announces the appointment of Renata Berardocco as Executive Vice President and Managing Director for the Latin America (LATAM) region. Renata has nearly two decades of experience in senior leadership roles and joins from Fortrea, … Read more

Respiratory Health Priorities are Changing Across Europe – What Role Do Clinical Trial Sites Have to Play?

November 20, 2024

For decades, research into respiratory health has centered on conditions such as asthma and chronic obstructive pulmonary disease (COPD), predominantly because of their high prevalence. However, the incidence of respiratory diseases is increasing globally, with lesser-researched but equally debilitating conditions such as interstitial lung … Read more

Henrick Watz, MD, PhD, Leads Ahrensburg, Germany Site as Top Enroller in Global COPD Trial

November 19, 2024

Another outstanding achievement for Henrik Watz, MD, PhD, and our team in Ahrensburg, Germany! They led enrollment for a global chronic obstructive pulmonary disease (COPD) trial, more than doubling the enrollment of the next highest-performing site. Congratulations to Dr. Watz and our Ahrensburg team! … Read more

Kris Kowdley, MD, Presents Positive Late-Breaking Data for Ipsen’s Iqirvo® at AASLD

November 18, 2024

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, presented late-breaking data for Iqirvo® (elafibranor), Ipsen’s treatment for primary biliary cholangitis (PBC), at American Association for the Study of Liver Diseases (AASLD). “Over three years, Iqirvo data suggest sustained efficacy and support the safety profile of … Read more

The Start of Germany’s National Pharma Strategy: Implications for CROs and Clinical Trials

November 12, 2024

Over the past decade, Germany’s share of global clinical trial activities has dropped year on year. The country accounted for just 3.9% of trials in 2021, down from 7.2% in 2012. Late last year, the German Government published its National Pharma Strategy, which is … Read more

Velocity Enrolled 8,000+ Participants in Trials in October

November 7, 2024

Velocity enrolled more than 8,000 participants in clinical trials in October, marking our highest-ever enrollment in a single month. This required many long hours and thoughtful solutioning from so many across the organization. A special thank you to our site staff and Recruitment team, … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.